Headlines about Insulet (NASDAQ:PODD) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Insulet earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.8053969295982 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Insulet (NASDAQ:PODD) opened at $68.49 on Friday. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. The stock has a market capitalization of $4,014.96, a PE ratio of -136.98 and a beta of 1.58. Insulet has a 52 week low of $36.80 and a 52 week high of $72.99.
Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million during the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) earnings per share. sell-side analysts expect that Insulet will post -0.43 earnings per share for the current fiscal year.
In other Insulet news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by insiders.
WARNING: This article was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3126207/insulet-podd-receives-coverage-optimism-score-of-0-12.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.